Summary.-Several radiotherapeutic schedules compatible with continued structural-functional integrity of the gastrointestinal (GI) mucosa were compared utilizing the P815X2 murine mastocytoma grown as a solid subcutaneous tumour. Both the tumour and underlying normal tissues were irradiated during the treatments. The tumour exhibited a Do that increased from 210 rad to 397 rad as the tumour aged and in all instances demonstrated minimal shoulders in survival curves. In spite of a relative radioresistance of cells within the solid tumour, quite effective control of localized disease could be accomplished with radiotherapy schemes compatible with GI tolerance limits.
Schedules evaluated utilizing this model included acute exposures to 1122 rad, daily exposure to 187 rad, 5 days/week exposures to 281 rad, twice weekly exposures (561 rad on Mondays and 374 rad on Thursdays) and a high dose, two fractions per day, schedule. Tumours were followed for changes in growth patterns during these schedules. Efficacy of tumour control was determined and schedules were compared on this basis. Aggressive radiotherapy approaching the tolerance limits of any of the fractionation schemes proved most effective.
IN THE present communication we evaluate the efficacy of several radiotherapeutic approaches used for the treatment of localized subcutaneous tumours and report results of fractionated exposure schedules that are limited by normal tissue (underlying gastrointestinal mucosa) tolerance. Seven days per week, 5 days per week, intermittent high dose schedules and acute exposure experiments were selected so that intact, functional gastrointestinal mucosa would be maintained throughout the therapeutic efforts. The P81 5X2 murine mastocytoma used in these studies demonstrates many characteristics which are advantageous in a model system: The tumour may be grown and evaluated in DBA/2 mice as a solid subcutaneous primary, in metastatic foci or as an ascites tumour. It is responsive to chemotherapeutic (Hagemann, Schenken, and Lesher, 1973; Hagemann, et al. unpublished) , immunological (Faanes, Choi and Good, 1973) and radiotherapeutic manipulation. The tumour grows in a predictable fashion following subcutaneous implantation, metastasizes to lung, spleen and lymph nodes in an ordered pattern, and demonstrates invasiveness and differentiation patterns similar to many human neoplasms (Schenken, et al. unpublished) .
MNIATERIALS AND METHODS
Tuonur. The P815X2 murine mastocytoma used in these studies wras originally described by Dunn and Potter (1957) . The cells are maintained in our laboratory by serial inoculation of suspension type cultures as described by Schindler, Day and Fisher (1959 glycoprotein content and heightened histamine granularity in many older tumours is also consistent with a picture of greater cellular differentiation.
The growth patterns seen following single exposures given to 7-day old P815X2 tumours are shown in Fig. 1 and are summarized in Table 11; Fig. 4) . The greatest control of local disease resulted from the 561 rad Monday + 374 rad Thursday schedule.
In order to compare efficiencies of tumour control per unit of radiation exposure, the calculations summarized in the column entitled " treatment efficiency" were made. Treatments resulting in no control of the primary result in TE values of 0 00; treatments that result in effective control of local disease result in TEs that are correspondingly higher. If a treatment resulted in tumour growth greater than would result from sham treatment the TE would be a negative number. Thus expressed, the most inefficient method of tumour control would be the 5 days/week schedule and the most efficient method used would be the 561 rad Monday and 374 rad Thursday schedule.
DISCUSSION
Our initial approach to evaluating the radiotherapeutic responsiveness of solid subcutaneous P81 5X2 tumours involved definition of a model whereby critical normal tissue would, of necessity, be irradiated concomitantly with local tumour. We chose the lower back for the site of subcutaneous inoculation, thereby requiring that any radiation beam incident to the tumour would irradiate a substantial portion of the underlying colon and small intestine. Data presented by Lesher and Lesher (1974) , Hagemann et al. (unpublished) , and Hagemann, Sigdestad and Lesher (1972) suggested the following general guidelines for gastrointestinal tolerance following total abdominal radiation exposures: (1) Generally, exposures in excess of 1216 rad/week are not well tolerated by the intestinal mucosa; (2) similarly, multifraction daily exposures to the gut should be less than 281 rad/fraction; (3) a schedule of 935 rad in 2 days will be well tolerated if divided doses of 234 rad/fraction are used; (4) 561 rad represents an exposure which will alter mucosal cellularity but will not alter P81i,5X2 RADIOTHERAPEUTIC CONTROL crypt multiplicity. Repeated exposures of 561 rad could, with adequate time for interfraction repopulation, be well tolerated.
Several general aspects for the P81.5X2 tumour also relate to considerations of the model: (1) Cloning data suggest that by Day 7 post-inoculation, metastatic growth is minimal, yet detectable; (2) almost all cells in the primary tumour are clonogenic; are capable of sustained proliferation; and from data presented in this paper: (3) the cells within a solid P815X2 tumour do not have much capacity for the accumulation and/or the repair of radiation damage (low extrapolation number and narrow shoulder for both young and old tumours); (4) the Do range of 210-407 rad indicates a cell type which is not excessively sensitive to radiation exposure.
A limited approach to the radiotherapeutic control of local disease (the solid P81 5X2 subcutaneous primary) evolved from such considerations of normal tissue tolerance and tumour responsiveness. The model further imposed that when the animal presented for therapy local disease was quantifiable and that metastatic involvement had already occurred. We know from the onset of our experiments that although local disease might be successfully eliminated, animals would eventually die from metastatic burden. We have successfully designed a surgical technique whereby the subcutaneous tumour could be removed at Day 7 and animals would then live to 34 days post inoculation instead of the normal 26 days (unpublished observation). Therefore it was thought that a truly successful radiotherapeutic approach to the control of local disease should result in an increased lifespan approaching this order of magnitude, and that control of the primary should be established as early as possible after Day 6. In all probability these results of aggressive radiotherapeutic efforts would approach the configuration one would expect using " optimal " efforts at ablating localized P815X2 disease. The increased control of tumour growth as exposure per fraction increased seen for the 7 days/week schedules (Fig.  2) and the 5 days/week schedules (Fig. 3) is not surprising for the cell survival data presented in Table I suggest that there is very little shoulder to the survival curves; small increases in exposure per fraction will generate differences in cell kill that will eventually be manifest as changes in tumour size. Yet cell killing per se cannot account for all the differential effects seen in these series. It must be considered that the subcutaneous P815X2 tumour does not contain a static population of cells at risk to fractionated radiotherapy. Such experi-mental tumours generally have shown several characteristics that determine overall radioresponsiveness to fractionated radiation exposure. These characteristics include interfraction repair of sublethal damage, redistribution of cells within the proliferative compartment, reoxygenation of tumour tissue and repopulation of proliferative compartments by recruitment of quiescent cells and/or shortening of mean cell cycle times.
The data presented in Fig. 3 
